Altanine

What Altanine does

Altanine is a specialty pharmaceutical company founded in 2023 and headquartered in Los Angeles, with additional offices reported in London and Shanghai. The company is developing reformulated versions of established small-molecule drugs using four proprietary drug delivery platforms: enteric coating, microencapsulation, inhalation formulation, and chewable dosage forms. Its disclosed product candidates include a chewable Metformin tablet (diabetes), an inhalable Sildenafil formulation (sexual wellness), an inhalable Sumatriptan formulation (migraine), and a coated Semaglutide capsule (weight control/diabetes), targeting addressable markets across diabetes, weight control, sexual wellness, and neurocare.

The company's claimed intellectual property portfolio spans 400+ drug families, though the legal status of these assets (granted patents vs. pending applications vs. trade secrets) is not disclosed in the available data. Altanine is pursuing the FDA 505(b)(2) regulatory pathway for its candidates, which allows reliance on existing safety and efficacy data of approved reference listed drugs and may confer multi-year market exclusivity upon approval. Near-term revenue is generated exclusively through the 503A compounding pharmacy channel under U.S. federal regulations, which permits patient-specific formulations but caps scale relative to mass-market commercialization.

The company is privately held, operates with 11-50 employees, and is undergoing a pending merger with Polomar Health Services announced 15 May 2025, which is positioned to provide a public-market vehicle. Leadership has been substantially rebuilt in 2025-2026, including a new CEO (Charles Andres, July 2025), a new CFO (Patrice Launay, January 2026), and two additions to the Scientific Advisory Board. No disclosed revenue, funding rounds, or AI/ML capabilities appear in the available data.

Name

Altanine

Legal name

Altanine Inc.

Website

https://altanine.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Altanine is a specialty pharmaceutical company developing reformulated small-molecule drugs using proprietary drug delivery platforms (enteric coating, microencapsulation, inhalation, chewable) across diabetes, weight control, sexual wellness, and neurocare, monetized via 503A compounding pharmacies pending FDA 505(b)(2) approvals.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE), Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Drug delivery technology
• Enteric coating formulations
• Specialty pharmaceuticals
• Compounding pharmacy products
• Alternative drug delivery

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Compounding Pharmacy Sales: Products sold through 503A compounding pharmacies in the United States as an immediate revenue-generating platform, with plans to commercialize or license additional products including CBD and other coating technology applications.
2. FDA 505(b)(2) Pipeline: Potential for FDA 505(b)(2) approval pathway in or prior to 2027 for drug delivery innovations including dry powder inhalers and chewable tablets, enabling licensing opportunities.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Altanine is a specialty pharmaceutical company that develops proprietary enteric coating and microencapsulation drug delivery technologies and sells reformulated versions of established active pharmaceutical ingredients (Metformin chewable, Sildenafil inhalable, Sumatriptan inhalable, Semaglutide coated capsule) for diabetes, weight control, sexual wellness, and neurocare. Products are commercialized through 503A compounding pharmacies in the United States while the company pursues FDA 505(b)(2) regulatory approval for alternative dosage forms.

Product overview

Altanine is a specialty pharmaceutical company developing proprietary enteric coating and microencapsulation technologies to enhance drug delivery. The company markets a portfolio of reformulated medications targeting diabetes, weight control, sexual wellness, and neurocare markets. Current products include: Metformin (chewable gummy with enteric coating for improved bioavailability and reduced GI side effects), Sildenafil (inhalable version for faster ED treatment), Sumatriptan (inhalable formulation for rapid migraine relief), and Semaglutide (coated oral capsules as an alternative to injectable GLP-1 therapy). The company sells through compounding pharmacies while pursuing FDA 505(b)(2) approval.

Differentiator

Problem solved

Functional benefit

Products and services

• Metformin (chewable gummy with proprietary enteric coating) A chewable gummy formulation of Metformin using proprietary enteric coating, aimed at improving compliance, reducing gastrointestinal adverse events, and enhancing bioavailability for type 2 diabetes and PCOS patients.
• Sildenafil (inhalable formulation) An inhalable version of Sildenafil providing faster, more effective, and convenient delivery compared with oral pills, intended for erectile dysfunction and pulmonary arterial hypertension.
• Sumatriptan (inhalable formulation) An inhalable Sumatriptan formulation that targets migraine pain relief within about 15 minutes, intended to reduce side effects and lower required doses compared with oral Sumatriptan.
• Semaglutide (coated oral capsules) Coated oral capsules for GLP-1 drugs such as Semaglutide that replace syringe injections with an easier-to-administer format while increasing efficacy and stability.

Quantifiable outcome

• Metformin enteric coating delivers 85%+ bioavailability to the small intestine
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Polomar Health ServicescoreOthers · 15 May 2025Polomar Health Services, Inc. and Altanine, Inc. agreed to waive certain closing conditions and amend their merger agreement, requiring Polomar to deliver updated audited financial statements prepared by a PCAOB-registered firm prior to closing. The parties also allowed Altanine to grant a security interest in assets of its subsidiary Pinata Holdings, Inc. and all Altanine assets to CWR 1, LLC. This represents a pending merger transaction between the two companies.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Noven Pharmaceuticals: Established drug-delivery company (transdermal patches) and a unit of Hisamitsu. Comparable focus on novel delivery routes for established molecules, with broader portfolio and commercialization scale.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with significant specialty and reformulated products. Relevant incumbent given Altanine's focus on improving established molecules like Sumatriptan and Metformin.
• Pfizer: Originator/developer of multiple drugs in Altanine's target space (Sildenafil via Viagra franchise, Sumatriptan via Relpax, oral GLP-1 research). Sets the competitive standard Altanine must beat on efficacy, safety, and commercial reach.

Direct peers

• Impel Pharmaceuticals (Jaguar Health): Specialty pharma focused on intranasal drug delivery reformulations (e.g., Trudhesa for migraine). Directly comparable to Altanine's inhalable Sumatriptan and Sildenafil programs and the 505(b)(2) approach to reformulating established molecules.
• Supernus Pharmaceuticals: Specialty CNS pharma with novel reformulations and drug-delivery technologies (e.g., Trokendi XR, Oxtellar XR). Comparable model of reformulating established molecules via differentiated delivery to extend franchises.
• Osmotica Pharmaceutical: Specialty pharma built around novel drug-delivery platforms applied to established molecules. Highly comparable operating model to Altanine's enteric coating and microencapsulation-based reformulations.
• Cingulate Therapeutics: Clinical-stage pharma developing precision-delivery reformulations of CNS drugs (e.g., ADHD). Closely comparable in pursuing novel dosage forms for established molecules through the 505(b)(2) pathway.
• Zevra Therapeutics: Rare-disease specialty pharma built around reformulations and novel delivery of established active ingredients. Comparable 505(b)(2) strategy and small commercial-stage profile.
• Collegium Pharmaceutical: Specialty pharma commercializing abuse-deterrent and reformulated pain/CNS products. Closely comparable business model of reformulating established molecules with delivery innovation.

Others

• Catalent: Major CDMO with deep drug-delivery, softgel, and oral formulation capabilities. Comparable technology stack to Altanine's enteric coating and microencapsulation, but operates as an enabler/contract manufacturer rather than a sponsor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/altanine

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altanine